Optimizing the Effect of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Migraine
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Migraine Disorders
- Sponsor
- Universidade Federal de Pernambuco
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Changes on VAS
- Last Updated
- 9 years ago
Overview
Brief Summary
The aim of this study is to establish an optimized protocol of tDCS that normalize the lack of habituation and efficiency of inhibitory cortical circuits in migraine patients and determine tDCS polarity and the best cortical areas to stimulate which could normalize the lack of habituation and efficiency of inhibitory cortical circuits. For this, migraineurs volunteers will undergo to some tDCS protocols or sham tDCS.
Detailed Description
A crossover trial to establish an optimized tDCS protocol will be accomplished. Anodal and cathodal tDCS will be applied over the primary motor cortex (C3 - active and contralateral supra-orbital region - reference) and visual cortex (Oz - active and Cz - reference). Dual tDCS (anodal and cathodal - optimized protocol) will be applied on C3 - active and Oz - active. Electrical cortical activity will be assessed on 14 migraineurs through: (i) MEP; (ii) MT; (iii) SICI; (iv) ICF; (v) PT and (vi) visual evoked-potential (VEP-habituation). An interval of 48hs between sessions will be taken. The order of the sessions will be randomized and counterbalanced among volunteers by site www.randomization.com.
Investigators
Kátia Monte-Silva
Principal Investigator
Universidade Federal de Pernambuco
Eligibility Criteria
Inclusion Criteria
- •Ages: 18-55 years
- •Gender: Both
- •Presented diagnostic of episodic migraine with or without aura or probably migraine with or without aura according to the criteria for diagnosis of ICHD-III
- •Disease duration of at least 12 months
- •Without preventive medication for at least 6 months prior to initiation of treatment
Exclusion Criteria
- •Pregnant women;
- •Pacemaker;
- •History of seizures;
- •Metallic implants in the head;
- •Patients with clinical evidence of brain injuries;
- •Chronic pain associated to others diseases;
- •Use of neuroleptic medications
Outcomes
Primary Outcomes
Changes on VAS
Time Frame: through study completion, assessed up to 3 weeks (before and after each section)
this scale will be used to measure the patients' pain intensity. VAS is an important instrument to verify, reliably, the patient's evolution during treatment. This scale will be used at beginning and end of each period (observation and treatment), before and after each tDCS session. For the VAS use, pain intensity will be asked to the patient. 0 cm means total pain absence and 10 cm is the level of maximum pain bearable by the patient.
Secondary Outcomes
- Changes on Visual Evoked Potentials measures(through study completion, assessed up to 3 weeks (before and after each section))
- Changes from phosphene threshold(through study completion, assessed up to 3 weeks (before and after each section))
- Changes on motor evoked potentials(through study completion, assessed up to 3 weeks (before and after each section))
- Changes on intracortical inhibition(through study completion, assessed up to 3 weeks (before and after each section))
- Changes on intracortical facilitation(through study completion, assessed up to 3 weeks (before and after each section))